Overview
CJC-1295 + Ipamorelin is a research combination studied for growth-hormone release and related signaling pathways. Researchers examine how the two compounds interact with different hormone-signaling mechanisms. Alpha Tides PNW supplies this blend strictly for laboratory research use.
Technical Research Details
The CJC-1295 + Ipamorelin blend is a dual-compound research blend combining two mechanistically distinct growth hormone secretagogues into a single lyophilized vial. Each compound targets a different receptor in the growth hormone axis, making the combination a well-studied model for examining how dual-pathway stimulation affects GH secretion patterns in research settings.
5MG CJC 1295 + 5MG Ipamorelin — 10MG total.
How Each Compound Works
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland over an extended period, facilitating long-term GH signaling. Ipamorelin is a selective ghrelin receptor agonist that stimulates faster, more immediate pulses of GH release with limited interaction with stress-related hormones.
The reason they are studied together comes down to timing. Ipamorelin’s receptor-mediated activity is observed earlier in the response profile, potentially priming GH release, while CJC-1295’s prolonged receptor engagement sustains GH-related activity through continued stimulation of the GHRH pathway. Together they produce what researchers describe as both a baseline and pulsatile release pattern — closer to natural GH secretion rhythm than either compound achieves alone.
Research Applications
- GH-axis pharmacology: Examining complementary GHRH and ghrelin-receptor pathways under controlled experimental conditions
- Pulsatile secretion modeling: Studying baseline versus pulsatile GH release patterns in preclinical models
- IGF-1 signaling research: Investigating downstream IGF-I response following sustained GH stimulation
- Receptor selectivity studies: Comparing Ipamorelin’s selectivity profile against older, less selective secretagogues
- Combination protocol design: Modeling how dual-compound stimulation differs from single-compound administration
Where the Research Stands
Preclinical research has examined CJC-1295’s ability to elevate GH and IGF-I levels over extended periods following administration in research models. Ipamorelin has been noted for its selectivity — unlike older compounds in its class, it does not appear to significantly stimulate cortisol or prolactin in preclinical models, which has made it a preferred subject for GH axis research.
Storage & Handling
- Before reconstitution: Store lyophilized vials at −20°C, away from light and moisture. Allow to reach room temperature before opening.
- After reconstitution: Refrigerate at 2–8°C and use within 14–28 days. Avoid repeated freeze-thaw cycles.
- Recommended solvent: Bacteriostatic water.
Related Research
- What Is CJC-1295 + Ipamorelin? A Researcher’s Guide — Full mechanism breakdown
- Multi-Compound Research Protocols — Combination study design considerations
- Tesamorelin — Related GHRH-analog research compound
- Certificates of Analysis — available for select products
Research Use Only
The CJC-1295 + Ipamorelin blend is intended strictly for laboratory research by qualified professionals. It is not FDA approved and is not for human or animal use. By purchasing, the buyer confirms the product will be used solely for in vitro research in compliance with all applicable laws and regulations.
Laboratory Testing
Certificate available
